Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.66 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2022-03-30
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $1.66M, a 35.84% increase from fiscal 2020.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $1.22M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2021-12-31 | $1.66M 10-K · filed 2022-03-30 |
| 2020-12-31 | $1.22M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |